Opus Genetics (IRD) Competitors $1.06 0.00 (0.00%) (As of 04:25 PM ET) Add Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsTrends IRD vs. ANL, ALLK, ELYM, BNTC, KPTI, DERM, FBLG, MCRB, ME, and ADAGShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Adlai Nortye (ANL), Allakos (ALLK), Eliem Therapeutics (ELYM), Benitec Biopharma (BNTC), Karyopharm Therapeutics (KPTI), Journey Medical (DERM), FibroBiologics (FBLG), Seres Therapeutics (MCRB), 23andMe (ME), and Adagene (ADAG). These companies are all part of the "pharmaceutical preparations" industry. Opus Genetics vs. Adlai Nortye Allakos Eliem Therapeutics Benitec Biopharma Karyopharm Therapeutics Journey Medical FibroBiologics Seres Therapeutics 23andMe Adagene Adlai Nortye (NASDAQ:ANL) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Does the media prefer ANL or IRD? In the previous week, Adlai Nortye had 3 more articles in the media than Opus Genetics. MarketBeat recorded 6 mentions for Adlai Nortye and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.00 beat Adlai Nortye's score of 0.89 indicating that Opus Genetics is being referred to more favorably in the news media. Company Overall Sentiment Adlai Nortye Positive Opus Genetics Positive Which has more risk and volatility, ANL or IRD? Adlai Nortye has a beta of -1.26, suggesting that its share price is 226% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Do analysts recommend ANL or IRD? Adlai Nortye presently has a consensus price target of $9.00, indicating a potential upside of 188.46%. Opus Genetics has a consensus price target of $8.00, indicating a potential upside of 654.72%. Given Opus Genetics' higher possible upside, analysts clearly believe Opus Genetics is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ANL or IRD? Adlai Nortye received 7 more outperform votes than Opus Genetics when rated by MarketBeat users. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesOpus GeneticsOutperform Votes1100.00% Underperform VotesNo Votes Is ANL or IRD more profitable? Adlai Nortye has a net margin of 0.00% compared to Opus Genetics' net margin of -324.45%. Adlai Nortye's return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Opus Genetics -324.45%-63.65%-56.94% Which has preferable valuation and earnings, ANL or IRD? Opus Genetics has higher revenue and earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M23.03-$104.87MN/AN/AOpus Genetics$19.05M1.76-$9.99M-$1.09-0.97 Do insiders and institutionals have more ownership in ANL or IRD? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 6.6% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAdlai Nortye beats Opus Genetics on 8 of the 14 factors compared between the two stocks. Ad DTICrypto’s Hidden Gem: The missing piece no one’s talking aboutYou don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.46M$6.46B$5.06B$8.69BDividend YieldN/A8.04%4.97%4.05%P/E Ratio-0.977.66113.2115.54Price / Sales1.76372.251,271.7586.38Price / CashN/A53.5139.8536.41Price / Book0.979.306.295.85Net Income-$9.99M$153.75M$118.80M$225.13M7 Day PerformanceN/A-6.58%-3.61%-2.13%1 Month PerformanceN/A-1.22%-0.25%2.50%1 Year PerformanceN/A30.75%32.06%23.63% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics2.3419 of 5 stars$1.06flat$8.00+654.7%N/A$33.46M$19.05M-0.97N/AEarnings ReportAnalyst ForecastAnalyst RevisionPositive NewsANLAdlai Nortye3.1439 of 5 stars$3.20+2.9%N/A-64.1%$118.08M$5M0.00127Short Interest ↓News CoverageALLKAllakos4.3438 of 5 stars$1.30-5.5%N/A-35.5%$115.70MN/A-0.64131Gap UpELYMEliem TherapeuticsN/A$3.80-6.4%N/A+39.5%$113.06MN/A-7.1720Gap DownBNTCBenitec Biopharma2.3024 of 5 stars$10.65-2.0%N/A+187.3%$112.46M$80,000.000.0020Short Interest ↑News CoverageKPTIKaryopharm Therapeutics4.1437 of 5 stars$0.89-0.4%N/A+9.5%$112.05M$146.03M-0.78380Analyst UpgradePositive NewsDERMJourney Medical3.0716 of 5 stars$5.33-2.2%N/AN/A$110.49M$79.18M-266.5090Short Interest ↓FBLGFibroBiologics2.1788 of 5 stars$3.14-0.9%N/AN/A$110.40MN/A0.0010Analyst ForecastAnalyst RevisionNews CoverageMCRBSeres Therapeutics4.0128 of 5 stars$0.64-4.2%N/A-52.3%$108.26M$126.32M-0.54233Analyst ForecastNews CoverageGap UpME23andMe1.3144 of 5 stars$4.39-6.8%N/A-77.3%$107.60M$219.64M-0.17770Earnings ReportShort Interest ↑Gap DownADAGAdagene3.2041 of 5 stars$2.40-2.0%N/A+69.3%$106.25M$18.11M0.00260Short Interest ↓Gap Up Related Companies and Tools Related Companies Adlai Nortye Alternatives Allakos Alternatives Eliem Therapeutics Alternatives Benitec Biopharma Alternatives Karyopharm Therapeutics Alternatives Journey Medical Alternatives FibroBiologics Alternatives Seres Therapeutics Alternatives 23andMe Alternatives Adagene Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IRD) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
